Discover
RVNC
Revance Therapeutics, Inc.
3.65
undefined x undefined
undefined x undefined
bid
ask
+
0.00
0.00%
04:00 PM
| Ytd | 20.07% | |
| 1y | -39.37% |
3.65
day range
3.65
52 week range
| Open | 3.65 | Prev Close | 3.65 | Low | 3.65 | High | 3.65 | Mkt Cap | N/A |
| Vol | 0.00 | Avg Vol | 0.00 | EPS | N/A | P/E | N/A | Forward P/E | -3.23 |
| Beta | 0.95 | Short Ratio | 5.20 | Inst. Own | 82.89% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | N/A | 200-d Avg | N/A | 1yr Est | 7.64 |
| Income Statement | |||
| Total Revenue | 59.88M | ||
| Revenues (USD) | 59.88M | ||
| Cost of Revenue | 17.63M | ||
| Gross Profit | 42.25M | ||
| Operating Expenses | 74.50M | ||
| Research and Development Expense | 11.38M | ||
| Selling, General and Administrative Expense | 62.58M | ||
| Operating Income | -32.26M | ||
| Interest Expense | 6.73M | ||
| Income Tax Expense | 1.50M | ||
| Net Income | -38.11M | ||
| Net Income Common Stock | -38.11M | ||
| Net Income Common Stock (USD) | -38.11M | ||
| Consolidated Income | -38.11M | ||
| Earnings per Basic Share | -0.37 | ||
| Earnings per Basic Share (USD) | -0.37 | ||
| Earnings per Diluted Share | -0.37 | ||
| Earning Before Interest & Taxes (EBIT) | -29.88M | ||
| Earning Before Interest & Taxes (USD) | -29.88M | ||
| Weighted Average Shares | 104.21M | ||
| Weighted Average Shares Diluted | 104.21M | ||
| Balance Sheet | |||
| Cash and Equivalents | 59.05M | ||
| Cash and Equivalents (USD) | 59.05M | ||
| Investments | 131.06M | ||
| Investments Current | 125.49M | ||
| Investments Non-Current | 5.56M | ||
| Trade and Non-Trade Receivables | 48.26M | ||
| Current Assets | 329.69M | ||
| Property, Plant & Equipment Net | 76.99M | ||
| Total Assets | 461.56M | ||
| Debt Current | 27.36M | ||
| Total Debt | 483.45M | ||
| Current Liabilities | 80.05M | ||
| Debt Non-Current | 456.08M | ||
| Total Liabilities | 624.59M | ||
| Accumulated Retained Earnings (Deficit) | -2.21B | ||
| Accumulated Other Comprehensive Income | 72.00K | ||
| Shareholders Equity | -163.03M | ||
| Shareholders Equity (USD) | -163.03M | ||
| Assets Non-Current | 131.88M | ||
| Total Debt (USD) | 483.45M | ||
| Deferred Revenue | 91.88M | ||
| Goodwill and Intangible Assets | 7.63M | ||
| Inventory | 85.21M | ||
| Liabilities Non-Current | 544.54M | ||
| Trade and Non-Trade Payables | 12.34M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 1.25M | ||
| Net Cash Flow from Financing | -6.09M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | -23.88M | ||
| Capital Expenditure | -61.00K | ||
| Issuance (Purchase) of Equity Shares | 5.00K | ||
| Issuance (Repayment) of Debt Securities | -5.72M | ||
| Net Cash Flow from Investing | 23.29M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | 23.35M | ||
| Net Cash Flow from Operations | -41.09M | ||
| Share Based Compensation | 4.58M | ||